CSIMarket
 


Quidel Corporation  (QDEL)
Other Ticker:  
 
 

QDEL's EPS Net Growth by Quarter and Year

Quidel's EPS Net results by quarter and year




QDEL EPS Net (in $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 5.48 0.71 0.60
III Quarter September - 5.33 0.38 0.27
II Quarter June 0.45 1.55 0.03 -0.08
I Quarter March 4.09 0.93 0.60 0.86
FY   4.54 13.29 1.72 1.65



QDEL EPS Net second quarter 2021 Y/Y Growth Comment
Quidel Corporation reported drop in EPS Net in the second quarter by -70.97% to $ 0.45 , from the same quarter in 2020.
The fall in the second quarter Quidel Corporation's EPS Net compares unfavorably to the Company's average EPS Net doubling of 665.99%.

Looking into second quarter results within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher EPS Net growth. While Quidel Corporation' s EPS Net meltdown of -70.97% ranks overall at the positon no. 1548 in the second quarter.




QDEL EPS Net ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 671.83 % 18.33 % -
III Quarter September - 1302.63 % 40.74 % -
II Quarter June -70.97 % 5066.67 % - -
I Quarter March 339.78 % 55 % -30.23 % 104.76 %
FY   - 672.67 % 4.24 % -

Financial Statements
Quidel's second quarter 2021 EPS Net $ 0.45 QDEL's Income Statement
Quidel's second quarter 2020 EPS Net $ 1.55 Quarterly QDEL's Income Statement
New: More QDEL's historic EPS Net Growth >>


QDEL EPS Net (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 2.81 % 86.84 % 122.22 %
III Quarter September - 243.87 % 1166.67 % -
II Quarter June -89 % 66.67 % -95 % -
I Quarter March -25.36 % 30.99 % 0 % -
FY (Year on Year)   - 672.67 % 4.24 % -




EPS Net second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #99
Overall #1548

EPS Net Y/Y Growth Statistics
High Average Low
5066.67 % 665.99 % -87.86 %
(Jun 30 2020)   (Dec 31 2013)
EPS Net second quarter 2021 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #14
Healthcare Sector #99
Overall #1548
EPS Net Y/Y Growth Statistics
High Average Low
5066.67 % 665.99 % -87.86 %
(Jun 30 2020)   (Dec 31 2013)

EPS Net by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Quidel's Q/Q EPS Net Growth


EPS Net Q/Q Growth Statistics
High Average Low
1166.67 % 116.15 % -95 %
(Sep 30 2019)  


QDEL's II. Quarter Q/Q EPS Net Comment
In the II. Quarter 2021 Quidel Corporation reported fall in EPS Net sequentially by -89% to $ 0.45 , from $ 4.09 declared in the previous reporting period.

Even periodic circumstance that commonly energize II. Quarter 2021 results, were not able to recover the II. Quarter for the Quidel Corporation, Amber Janssens, Healthcare sector expert wrote.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher EPS Net quarter on quarter growth. While Quidel's EPS Net growth quarter on quarter, overall rank is 2110.


EPS Net Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #156
Overall #2110
EPS Net Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #156
Overall #2110
EPS Net Q/Q Growth Statistics
High Average Low
1166.67 % 116.15 % -95 %
(Sep 30 2019)  


QDEL's II. Quarter Q/Q EPS Net Comment
In the II. Quarter 2021 Quidel Corporation reported fall in EPS Net sequentially by -89% to $ 0.45 , from $ 4.09 released in the previous reporting period.

Even cyclical factors that normally elevate II. Quarter 2021 EPS Net, could not recover the II. Quarter for the Quidel Corporation, Amber Janssens, Healthcare sector expert wrote, she mentioned little skepticism for the Quidel's perspective, she sees further headwinds onward for the In Vitro & In Vivo Diagnostic Substances's company and mentioned that average sequential EPS Net growth is at 116.15% for the In Vitro & In Vivo Diagnostic Substances's company.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher EPS Net quarter on quarter growth. While Quidel's EPS Net growth quarter on quarter, overall rank is 2110.


Quidel's 12 Months EPS Net Growth Year on Year


EPS Net TTM Growth

12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
Cumulative EPS Net 12 Months Ending $ 15.35 $ 16.45 $ 13.29 $ 8.52 $ 3.57
Y / Y EPS Net Growth (TTM) 329.84 % 702.21 % 672.4 % 429.32 % 138.06 %
Year on Year EPS Net Growth Overall Ranking # 100 # 42 # 36 # 24 # 38
Seqeuential EPS Net Change (TTM) -6.69 % 23.79 % 55.93 % 138.66 % 74.15 %
Seq. EPS Net Growth (TTM) Overall Ranking # 1782 # 517 # 230 # 64 # 108




Cumulative EPS Net growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual EPS Net surge of 329.84% year on year, of $ 15 .
This marks a slow-down of the companys growth trends and from the 702.21% surge in Mar 31 2021.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month EPS Net growth. While EPS Net growth total ranking has deteriorated compare to previous quarter from 42 to 100.

EPS Net TTM Q/Q Growth Statistics
High Average Low
138.66 %
40.22 %
-59.99 %
 

EPS Net TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 19
Healthcare Sector # 9
Overall # 100

EPS Net TTM Y/Y Growth Statistics
High Average Low
702.21 %
301.9 %
4.27 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 119
S&P 500 # 1782
Cumulative EPS Net growth Comment
Assuming the Quidel's fiscal year would have ended in Jun 30 2021, Quidel would have reprted above average annual EPS Net surge of 329.84% year on year, of $ 15 .
This marks a slow-down of the companys growth trends and from the 702.21% surge in Mar 31 2021.

Among companies within the Healthcare sector 8 other companies have achieved higher trailing twelve month EPS Net growth. While EPS Net growth total ranking has deteriorated compare to previous quarter from 42 to 100.

EPS Net TTM Q/Q Growth Statistics
High Average Low
138.66 %
40.22 %
-59.99 %
 


EPS Net TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 19
Healthcare Sector # 9
Overall # 100

EPS Net TTM Y/Y Growth Statistics
High Average Low
702.21 %
301.9 %
4.27 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 119
S&P 500 # 1782




Other EPS Net Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS Net Growth Trends and Statistics
Healthcare Sector EPS Net Growth Statistics
EPS Net Growth Trends for overall market
QDEL's EPS Net Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS Net Growth
Lowest Ranking EPS Net Growth
EPS Net Growth for QDEL's Competitors
EPS Net Growth for Quidel's Suppliers
EPS Net Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar EPS Net surge for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %EPS Net for the quarter ending Jun 30 2021
Eli Lilly And Company-1.29%$ -1.290 
Bio rad Laboratories Inc -5.69%$ -5.692 
Corcept Therapeutics Inc-8.70%$ -8.696 
Zynex Inc-11.11%$ -11.111 
Lhc Group Inc-16.08%$ -16.084 
U S Physical Therapy Inc-17.17%$ -17.172 
Reynolds Consumer Products Inc -28.30%$ -28.302 
Chemed Corporation-29.94%$ -29.940 
Msa Safety Inc-30.43%$ -30.435 
Supernus Pharmaceuticals inc -33.85%$ -33.846 
Co diagnostics Inc -35.29%$ -35.294 
The Pennant Group Inc -40.00%$ -40.000 
Petmed Express Inc-43.59%$ -43.590 
Neurocrine Biosciences Inc -46.91%$ -46.914 
Hill rom Holdings Inc -47.14%$ -47.143 
Merck and Co Inc -48.31%$ -48.305 
Incyte Corp-49.24%$ -49.242 
Healthcare Services Group Inc -58.06%$ -58.065 
Molecular Templates Inc -58.82%$ -58.824 
Meridian Bioscience Inc -59.38%$ -59.375 
Sunlink Health Systems Inc-60.42%$ -60.415 
Pro Dex Inc-66.22%$ -66.224 
Vyne Therapeutics Inc -67.77%$ -67.769 
Hanger inc -67.90%$ -67.901 
Biogen Inc -68.82%$ -68.822 
Electromed Inc -68.90%$ -68.904 
Tivity Health Inc -70.69%$ -70.690 
Quidel Corporation-70.97%$ -70.968 
Amgen Inc -73.44%$ -73.443 
Alpha Pro Tech Ltd-73.91%$ -73.913 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DCI's Profile

Stock Price

DCI's Financials

Business Description

Fundamentals

Charts & Quotes

DCI's News

Suppliers

DCI's Competitors

Customers & Markets

Economic Indicators

DCI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071